Methods of treating restenosis
Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
1. A method of reducing restenosis in a subject following angioplasty, the method comprising directly administering to the injured blood vessel of said subject a nucleic acid that encodes a SERCA2a polypeptide, wherein the nucleic acid is a component of an adenovirus-based vector, thereby reducing restenosis.
2. The method of claim 1 , wherein the nucleic acid encodes SERCA2a operably linked to a viral promoter.
3. The method of claim 1 , wherein the nucleic acid encodes SERCA2a operably linked to an inducible promoter.
4. The method of claim 1 , wherein the nucleic acid is administered in an amount effective to reduce neointimal hyperplasia.
5. A method of reducing restenosis in a subject folloeing angioplasty, the method comprising directly administering to the injured blood vessel of said subject a nucleic acid that encodes a SERCA 2 a polypeptide, wherein the nucleic acid is a component of an adeno-associated virus-based vector, thereby reducing restenosis,
6. The method of claim 5 , wherein the nucleic acid encodes SERCA 2 a operably linked to a viral promoter.
7. The method of claim 5 , wherein the nucleic acid encodes SERCA 2 a operably linked to an inducible promoter.
8. The method of claim 5 , wherein the nucleic acid is administered in an amount effective to reduce neointimal hyperplasia.